- Post-Hoc: China deals are pharma’s new tax inversionsAbout a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...Endpoints · 29d ago↗ source
- Theravance, after clinical setbacks, agrees to $929M buyout<figure><div><img src="https://imgproxy.divecdn.com/adiJN9GDP_sdBKAPLoO1u858OLmoo_2c7bk4eved-BY/g:nowe:919:1/c:1869:1055/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlc…BioPharma Dive · 29d ago↗ source
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfrontIpsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...